MEDICURE APPROVED TO INITIATE PHASE II/III HYPERTENSION TRIALS.Medicure Inc. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :MPH), Winnipeg, Canada, a cardiovascular drug discovery and development company, has received approval from Canada's Therapeutic Products Directorate Therapeutic Products Directorate (TPD) is a Canadian federal authority that regulates pharmaceutical drugs and medical devices for human use, a role performed by the Food and Drug Administration in the United States. (TPD TPD Tons Per Day TPD Therapeutic Products Directorate TPD Total and Permanent Disablement (insurance) TPD Temperature Programmed Desorption TPD Temporary Partial Disability (insurance) ) to commence a Phase II trial as part of the development program for Medicure's second clinical candidate, MC-4232. The initial patients are being enrolled in the first of a series of exploratory trials in hypertension. Hypertension is a common disorder in which blood pressure remains abnormally high. Approximately 57 million adult North Americans have high blood pressure. Of those, 73% of them are not adequately controlled and have an increased risk of heart attack, stroke, kidney failure kidney failure or renal failure Partial or complete loss of kidney function. Acute failure causes reduced urine output and blood chemical imbalance, including uremia. Most patients recover within six weeks. , damage to the eyes, heart failure and atherosclerosis. This initial trial will enroll 15 patients with hypertension and is designed to determine an effective dose-range for future studies. It is expected that results from the trial will be available by the end of 2003. Commencing this study represents another major clinical milestone for Medicure and the tremendous potential treatment of another major unmet component of the cardiovascular market, stated Dr. Albert D. Friesen, PhD, Medicure's president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . This trial is an important step in the gathering of data that will eventually support Medicure moving forward to a larger, pivotal clinical trial of MC-4232. About Medicure Inc. Medicure Inc. is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine. The company's lead drug, MC-1, is focused on the prevention and treatment of ischemia, ischemic reperfusion ischemic reperfusion, n the restoration of blood flow to an area that had previously experienced deficient blood flow. Oxidative stresses associated with this situation may cause damage to the affected tissues or organs. injury, and stroke. The cardiovascular and stroke market is the largest pharmaceutical sector with annual global sales of over US $70 billion. In the United States alone, more than 7 million people suffer some form of Acute Myocardial Infarction acute myocardial infarction (  ·kyōōtˑ mī·ō·karˑ·dē· (heart attack) annually, 6.2 million suffer from angina and 1.6 million undergo bypass surgery or angioplasty procedure. Medicure also has a medicinal chemistry based Drug Discovery program focused on discovery and advancement of novel small molecules - anti-ischemics and anti-thrombotics - towards human clinical studies. For more information, call 888/435-2220 or visit http://www.medicureinc.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion